What one share of Estrella Immunopharma holds
We are a clinical-stage biopharmaceutical company developing T-cell therapies to address treatment challenges for patients with cancers and autoimmune diseases. Our strategy is to harness the evolutionary power of the human immune system to provide patients with potentially safer, more efficacious T-cell therapies compared to traditional CAR-T therapies.
Estrella Immunopharma’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.25 |
|---|---|
| Cash and investments | $0.00 |
| Book value | −$0.17 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$36.35 | — | — | — | — |
| 2024 | — | −$0.27 | — | — | — | $0.12 |
| 2025 | — | −$0.35 | — | — | — | −$0.27 |
Common questions about Estrella Immunopharma
How much does one share of Estrella Immunopharma earn?
Over the last 12 months, Estrella Immunopharma lost $0.25 for each share.
Does Estrella Immunopharma pay a dividend?
Estrella Immunopharma didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Estrella Immunopharma’s book value per share?
Estrella Immunopharma’s book value is negative (−$0.17 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Estrella Immunopharma have?
Each share of Estrella Immunopharma has $0.00 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.